Tyra Biosciences, Inc.
TYRATyra Biosciences is a clinical-stage biotechnology company specializing in next-generation precision medicines for targeted oncology and genetically defined conditions.
Earnings
Next report
Nov 4, 2026 (in 3 months)Valuation & ratios
Competitors
By market cap
Profile
Tyra Biosciences is a clinical-stage biotechnology company specializing in next-generation precision medicines for targeted oncology and genetically defined conditions. The company utilizes its proprietary SNÅP platform to design oral small molecule inhibitors that target Fibroblast Growth Factor Receptor (FGFR) biology with high selectivity and potency. Their primary focus is overcoming the toxicity and resistance limitations of first-generation FGFR therapies to address significant unmet needs in bladder cancer and skeletal dysplasia.
Tyra is a clinical-stage innovator leveraging a proprietary molecular design platform to develop highly selective FGFR3 inhibitors that potentially offer superior safety profiles compared to approved pan-FGFR therapies.
FAQ
- What is Tyra Biosciences, Inc.'s market cap?
- Tyra Biosciences, Inc. (TYRA) has a market capitalization of $1.6B and trades on NASDAQ.
- Who are Tyra Biosciences, Inc.'s competitors?
- Tyra Biosciences, Inc.'s key competitors include BridgeBio Pharma, BioMarin Pharmaceutical, Incyte Corporation, and others. These companies compete in similar markets and product categories.
- Who does Tyra Biosciences, Inc. partner with?
- Tyra Biosciences, Inc.'s notable partners include Johnson & Johnson, Imagine Institute.
- Where is Tyra Biosciences, Inc. headquartered?
- Tyra Biosciences, Inc. is headquartered in United States of America and employs approximately 38 people. It has been publicly traded since 2021.